PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, said that its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd. has received marketing approval in Korea from the country’s Ministry of Food and Drug Safety (MFDS) and the Korea Testing & Research Institute (KTR) for MuGard, its oncology supportive-care treatment for the management of oral mucositis. Under the terms of the previously announ...